NCT06172634View on ClinicalTrials.gov

A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Pancreas Cancer
Interventions
DRUG

dentritic cell infusion and immunecheckpoint inhibitor

dentritic cell infusion and immunecheckpoint inhibitor

All Listed Sponsors
lead

Soonchunhyang University Hospital

OTHER

NCT06172634 - A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy | Biotech Hunter | Biotech Hunter